Search results for " Hodgkin"

showing 10 items of 26 documents

Interleukin-31 and thymic stromal lymphopoietin expression in plasma and lymph node from Hodgkin lymphoma patients

2017

Hodgkin Lymphoma (HL) is a tumor of B-cell origin characterized by Hodgkin and Reed-Stenberg (H/RS) cells embedded in an inflammatory tissue where numerous cytokines/chemokines contribute to shape the microenvironment, leading to the typical clinical symptoms. We investigated: i) the expression of Interleukin-IL-31 (IL-31) and Thymic Stromal Lymphopoietin (TSLP), two Th2-related cytokines with tumor-promoting and pruritogenic functions, and of the respective receptors in HL invaded lymph nodes by flow cytometry, and ii) the potential association of IL-31/TSLP plasma concentrations with clinical characteristics by ELISA. H/RS cells and the major immune cell types infiltrating HL lymph nodes …

0301 basic medicineChemokineThymic stromal lymphopoietinIL-31cytokine receptorsFlow cytometryCytokine receptors; Hodgkin lymphoma; IL-31; PET; TSLP; Oncology03 medical and health sciencesImmune systemcytokine receptors; hodgkin lymphoma; IL-31; pet; tslp; oncologyMedicineReceptorLymph nodebiologymedicine.diagnostic_testbusiness.industryCytokine receptorSettore MED/15 - MALATTIE DEL SANGUEPET030104 developmental biologyInterleukin 31medicine.anatomical_structureOncologyTSLPImmunologybiology.proteinLymphbusinessHodgkin lymphomaResearch PaperOncotarget
researchProduct

The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma

2016

// Alessandra Romano 1 , Nunziatina Laura Parrinello 1 , Calogero Vetro 1 , Daniele Tibullo 1 , Cesarina Giallongo 1 , Piera La Cava 1 , Annalisa Chiarenza 1 , Giovanna Motta 1 , Anastasia L. Caruso 1 , Loredana Villari 2 , Claudio Tripodo 3 , Sebastiano Cosentino 4 , Massimo Ippolito 4 , Ugo Consoli 5 , Andrea Gallamini 6 , Stefano Pileri 7 , Francesco Di Raimondo 1 1 Division of Hematology, AOU “Policlinico - Vittorio Emanuele”, University of Catania, Catania, Italy 2 Division of Pathology, AOU “Policlinico - Vittorio Emanuele”, Catania, Italy 3 Tumor Immunology Unit, Department of Health Science, University of Palermo, Palermo, Italy 4 Nuclear Medicine Center, Azienda Ospedaliera Cannizz…

0301 basic medicineMaleCancer ResearchMyeloidNeutrophilsmedicine.medical_treatmentArginase-1Treatment outcomeKaplan-Meier EstimateGastroenterology0302 clinical medicineHematologyHealthy subjectsImmunosuppressionHematologyMiddle AgedPrognosisHodgkin DiseaseTreatment Outcomemedicine.anatomical_structureOncology030220 oncology & carcinogenesisFemaleArginase-1; Hodgkin Lymphoma; PET-2Tumor immunologyResearch PaperAdultmedicine.medical_specialtyPrognostic variableAdolescentAntineoplastic AgentsPET-2Sensitivity and SpecificityDisease-Free SurvivalYoung Adult03 medical and health sciencesInternal medicineBiomarkers TumormedicineHumansProgression-free survivalAgedArginasebusiness.industryMyeloid-Derived Suppressor Cells030104 developmental biologyPotential biomarkersImmunologyHodgkin lymphomabusinessHodgkin lymphoma030215 immunologyOncotarget
researchProduct

Follicular dendritic cells display microvesicle-associated LMP1 in reactive germinal centers of EBV+ classic Hodgkin lymphoma

2018

Expression of the latent membrane protein-1 (LMP1) of Epstein-Barr virus (EBV) was investigated in 153 cases of EBV+ classic Hodgkin lymphoma (cHL); 120 cases were pediatric patients (< 14 years of age) from Iraq, and 33 cases were adult patients from Italy. We describe for the first time the presence of LMP1 protein in EBV-encoded RNA (EBER)-negative follicular dendritic cells (FDCs) of reactive germinal centers (GC) associated with EBV+ cHL. Presence of LMP1+ GCs was independent of geographic region and age of patients. Variable numbers of reactive GCs were present in 22.2% of cases (34 of 153), whereas LMP1 staining of FDCs was present in about a third of cases (10 of 34) with reactiv…

0301 basic medicineMaleEpstein-Barr Virus InfectionsClassic Hodgkin lymphoma (cHL)CD30Follicular dendritic cells (FDCs)Exosomes and&nbsp0302 clinical medicineclassic hodgkin lymphoma (chl); epstein-barr virus (ebv); exosomes and microvesicles; follicular dendritic cells (fdcs); latent membrane protein-1 (lmp1); programmed death ligand 1 (pd-l1)Nodular sclerosisCell-Derived MicroparticlesEpstein-Barr Virus Infectionhemic and lymphatic diseasesChildCD63MicrovesicleGeneral MedicineMiddle AgedHodgkin DiseaseEpstein-Barr virus (EBV)Cell-Derived Microparticle030220 oncology & carcinogenesisProgrammed death ligand 1 (PD-L1)microvesicleOriginal ArticleFemaleHumanAdultBiologyVirusPathology and Forensic MedicineViral Matrix Proteins03 medical and health sciencesExosomes and microvesiclesmedicineotorhinolaryngologic diseasesHumansMolecular BiologyEpstein–Barr virus infectionAgedFollicular dendritic cellsGerminal centerCell Biologymedicine.diseaseGerminal CenterMolecular biologystomatognathic diseases030104 developmental biologyLatent membrane protein-1 (LMP1)Dendritic Cells Follicular
researchProduct

Genetically Determined Height and Risk of Non-hodgkin Lymphoma

2020

Although the evidence is not consistent, epidemiologic studies have suggested that taller adult height may be associated with an increased risk of some non-Hodgkin lymphoma (NHL) subtypes. Height is largely determined by genetic factors, but how these genetic factors may contribute to NHL risk is unknown. We investigated the relationship between genetic determinants of height and NHL risk using data from eight genome-wide association studies (GWAS) comprising 10,629 NHL cases, including 3,857 diffuse large B-cell lymphoma (DLBCL), 2,847 follicular lymphoma (FL), 3,100 chronic lymphocytic leukemia (CLL), and 825 marginal zone lymphoma (MZL) cases, and 9,505 controls of European ancestry. We …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyChronic lymphocytic leukemiaFollicular lymphomadiffuse large B-cell lymphomaSingle-nucleotide polymorphismGenome-wide association studylcsh:RC254-28203 medical and health sciences0302 clinical medicinefollicular lymphomaimmune system diseasesInternal medicinehemic and lymphatic diseasesGeneticsMedicineLeucèmia limfocítica crònicageneticsOriginal ResearchGenetic associationCancer och onkologibusiness.industrynon-Hodgkin lymphomaOdds ratiomedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmarginal zone lymphomaLymphomaMalaltia de Hodgkin030104 developmental biologyOncologyCancer and Oncology030220 oncology & carcinogenesispolygenic risk scorediffuse large B-celllymphomachronic lymphocytic leukemiaChronic lymphocytic leukemiaHodgkin's diseasegeneticbusinessDiffuse large B-cell lymphomaGenèticaheightFrontiers in Oncology
researchProduct

Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical hodgkin lymphoma and correlation with early FDG-PET a…

2017

In Hodgkin Lymphoma (HL), about 20% of patients still have relapsed/refractory disease and late toxic effects rate continue to rise with time. 'Early FDG-PET' and tissue macrophage infiltration (TAM) emerged as powerful prognostic predictors. The primary endpoint was to investigate the prognostic role of both early FDG-PET and TAM; the secondary endpoint was to test if early FDG-PET positivity could correlate with high TAM score. A cohort of 200 HL patients was analysed. Induction treatment plan consisted of two to six courses of ABVD and, if indicated, involved field radiation therapy. All patients repeated CT scan and FDG-PET after two cycles and after the completion of therapy. TAM in di…

AdultMaleAdolescentHodgkin’s lymphomaMacrophagePrognosiAntigens Differentiation MyelomonocyticVinblastineDisease-Free SurvivalCohort StudiesBleomycinYoung AdultAntigens CDFluorodeoxyglucose F18RecurrencePositron Emission Tomography Computed TomographyAntineoplastic Combined Chemotherapy ProtocolsHumansCD68AgedAged 80 and overHodgkin's lymphomahematologyMacrophagesCD68; Hodgkin's lymphoma; macrophages; PET; prognosis; hematology; oncology; cancer researchAntibodies MonoclonalMiddle AgedPrognosisHodgkin DiseaseImmunohistochemistryDacarbazineTreatment OutcomePETDoxorubicinPositron-Emission Tomographyoncologycancer researchFemaleNeoplasm Recurrence LocalFollow-Up Studies
researchProduct

A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus

2014

Contains fulltext : 137763.pdf (Publisher’s version ) (Open Access) Recent genome-wide association studies (GWAS) of Hodgkin lymphoma (HL) have identified associations with genetic variation at both HLA and non-HLA loci; however, much of heritable HL susceptibility remains unexplained. Here we perform a meta-analysis of three HL GWAS totaling 1,816 cases and 7,877 controls followed by replication in an independent set of 1,281 cases and 3,218 controls to find novel risk loci. We identify a novel variant at 19p13.3 associated with HL (rs1860661; odds ratio (OR)=0.81, 95% confidence interval (95% CI)=0.76-0.86, Pcombined=3.5 x 10(-10)), located in intron 2 of TCF3 (also known as E2A), a regul…

AdultMaleAdolescent[SDV]Life Sciences [q-bio]TRANSCRIPTION FACTOR E2AGENETIC-ASSOCIATIONGeneral Physics and AstronomyLocus (genetics)Genome-wide association studyHuman leukocyte antigenBiologyGeneral Biochemistry Genetics and Molecular BiologyArticleDISEASEYoung AdultBasic Helix-Loop-Helix Transcription FactorsHumansTOOLGenetic Predisposition to DiseaseAlleleGENOME-WIDE ASSOCIATIONEPSTEIN-BARR-VIRUSGenetic associationAgedGeneticsAged 80 and overRISKMultidisciplinaryCELL-TYPECase-control studyGenetic VariationGeneral ChemistryOdds ratioGenomicsMiddle AgedALLELESHodgkin DiseaseCANCERMalaltia de HodgkinHodgkin lymphoma (HL)GenòmicaGenetic epidemiologyCase-Control StudiesUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]Hodgkin's diseaseChromosomes Human Pair 19Genome-Wide Association Study
researchProduct

Anaplastic large cell lymphoma (CD30+/Ki-1+). Analysis of 35 cases followed at GISL centres

1995

Between January 1988 and June 1992, 35 patients with primary anaplastic large cell lymphoma (ALCL)CD30+ were referred to one of the institutions participating in GISL (Gruppo Italiano per lo Studio dei Linformi). 16 patients were treated with ProMACE-CytaBOM, two with MACOP-B, one with CHOP and one with LSA2-L2. As of November 1990, all newly diagnosed patients were treated with MOPP/EBV/CAD hybrid. 27 (77%) cases of ALCL CD30+ and 8 (23%) cases of Hodgkin's-related (HR) lymphoma CD30+ were diagnosed. Extranodal disease was present in 22 cases (63%), and 8 patients (23%) had primary bone marrow involvement. Twenty-three complete remissions (CR) (66%), six partial remissions (PR) (17%) and s…

AdultMaleCD30+ HODGKINS-RELATED LYMPHOMACancer Researchmedicine.medical_specialtyPathologyAdolescentCD30CHOPGastroenterologyExtranodal Diseaseimmune system diseaseshemic and lymphatic diseasesInternal medicineInduction therapyAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesAnaplastic large-cell lymphomaAgedbusiness.industryNON-HODGKINS LYMPHOMAMiddle Agedmedicine.diseaseLymphomaNon-Hodgkin's lymphomaSurvival RateRegimenTreatment OutcomeOncologyLymphoma Large-Cell AnaplasticFemaleANAPLASTIC LARGE CELL LYMPHOMA (CD30+/KI-1+)AGGRESSIVE CHEMOTHERAPYANAPLASTIC LARGE CELL LYMPHOMA (CD30+/KI-1+); CD30+ HODGKINS-RELATED LYMPHOMA; NON-HODGKINS LYMPHOMA; AGGRESSIVE CHEMOTHERAPYbusinessFollow-Up StudiesEuropean Journal of Cancer
researchProduct

Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomograp…

2009

Abstract Purpose In the pre—positron emission tomography era, the Gruppo Italiano Studio Linfomi (GISL) investigated the feasibility and efficacy of a treatment based on a response-tailored number of doxorubicin/bleomycin/vinblastine/dacarbazine (ABVD) courses in 218 intermediate-stage Hodgkin lymphoma patients. Patients and Methods Patients with stage I/II showing at least one adverse prognostic factor and stage IIIA without adverse prognostic factors were recruited. Treatment included a first step of 3 ABVD courses, followed by an early-restaging. Patients in CR/CRu received 1 additional ABVD cycle, patients in PR received 3 more ABVD, and nonresponder patients went off study. Involved-fi…

AdultMalemedicine.medical_specialtyCancer ResearchAdolescentDacarbazinemedicine.medical_treatmentEarly restagingVinblastineBleomycinYoung AdultAdolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Doxorubicin; Female; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Vinblastine; Young AdultAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansProspective StudiesStage (cooking)Prospective cohort studyAgedNeoplasm StagingChemotherapyAntineoplastic Combined Chemotherapy Protocolmedicine.diagnostic_testbusiness.industryGeneral MedicineHematologyMiddle AgedCombined Modality TherapyHodgkin DiseaseSurgeryVinblastineRadiation therapyDacarbazineProspective StudieABVDOncologyDoxorubicinErythrocyte sedimentation ratePositron-Emission TomographyFemaleRadiologybusinessmedicine.drugHumanClinical lymphomamyeloma
researchProduct

Caecal leiomyoma detected by whole-body MRI in a patient with Hodgkin lymphoma: first case report

2017

Introduction. Hodgkin Lymphoma (HL) is one of the most curable malignant diseases. Modern treatments, like the combined radiochemotherapy and stem cell transplantation, have increased the number of malignant disease survivors. However, HL survivors are at risk of long-term effects, including the development of solid tumors. Secondary neoplasms are a major cause of late morbidity and mortality following treatment for HL. Case report. We report the case of a male patient, treated for HL by chemotherapy, who developed a large leiomyoma of the cecum one year after the treatment. A whole-body Magnetic Resonance (WBMRI) scan performed during the follow-up allowed the detection of this incidental …

AdultMalemedicine.medical_specialtymedicine.medical_treatmentCecal NeoplasmsLaparoscopic surgeryBenign tumorLesionBiopsymedicineHumansWhole Body ImagingCaecal leiomyomaIncidental FindingsChemotherapyCaecal leiomyoma; Hodgkin lymphoma; Laparoscopic surgery; Magnetic resonance imaging; SurgeryLeiomyomamedicine.diagnostic_testbusiness.industryNeoplasms Second PrimaryMagnetic resonance imagingmedicine.diseaseHodgkin DiseaseMagnetic Resonance ImagingTransplantationSettore MED/18 - Chirurgia GeneraleLeiomyomaSurgeryOriginal ArticleRadiologyDifferential diagnosismedicine.symptomSettore MED/36 - Diagnostica Per Immagini E RadioterapiaTomography X-Ray ComputedbusinessHodgkin lymphomaGiornale di Chirurgia - Journal of Surgery
researchProduct

Whole-body MRI radiomics model to predict relapsed/refractory Hodgkin Lymphoma: A preliminary study.

2022

Purpose A strong prognostic score that enables a stratification of newly diagnosed Hodgkin Lymphoma (HL) to identify patients at high risk of refractory/relapsed disease is still needed. Our aim was to investigate the potential value of a radiomics analysis pipeline from whole-body MRI (WB-MRI) exams for clinical outcome prediction in patients with Hodgkin Lymphoma (HL). Materials and methods Index lesions from baseline WB-MRIs of 40 patients (22 females; mean age 31.7 ± 11.4 years) with newly diagnosed HL treated by ABVD chemotherapy regimen were manually segmented on T1-weighted, STIR, and DWI images for texture analysis feature extraction. A machine learning approach based on the Extra T…

AdultPositron emission tomographymedicine.medical_specialtyWhole body mriBiomedical EngineeringBiophysicsVinblastineBleomycinYoung AdultRefractoryRadiomicsPositron Emission Tomography Computed TomographyMachine learningAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansRadiology Nuclear Medicine and imagingMagnetic resonance imaging Positron emission tomography Machine learning Texture analysis Hodgkin Lymphomamedicine.diagnostic_testHodgkin Lymphomabusiness.industryMagnetic resonance imagingMetabolic tumor volumeHodgkin DiseaseMagnetic Resonance ImagingDacarbazineTexture analysisPositron emission tomographyDoxorubicinRelapsed refractoryHodgkin lymphomaFemaleRadiologySettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessMagnetic resonance imaging
researchProduct